Viva Biotech Holdings (HKSE:01873) Change In Receivables : HK$-28 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Change In Receivables?

Viva Biotech Holdings's change in receivables for the quarter that ended in Dec. 2024 was HK$-1 Mil. It means Viva Biotech Holdings's Accounts Receivable increased by HK$1 Mil from Jun. 2024 to Dec. 2024 .

Viva Biotech Holdings's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-28 Mil. It means Viva Biotech Holdings's Accounts Receivable increased by HK$28 Mil from Dec. 2023 to Dec. 2024 .

Viva Biotech Holdings's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$447 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Viva Biotech Holdings's Days Sales Outstanding for the six months ended in Dec. 2024 was 76.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Viva Biotech Holdings's liquidation value for the six months ended in Dec. 2024 was HK$-1,967 Mil.

Viva Biotech Holdings Change In Receivables Historical Data

The historical data trend for Viva Biotech Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Change In Receivables Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-51.71

-128.33

-23.67

30.72

-27.68

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial											18.54	107.01	-76.29	-27.36	-0.54

Viva Biotech Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-28 Mil.

Viva Biotech Holdings (HKSE:01873) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Viva Biotech Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	447.3	/	1072.826	*	91
=	76.09

2. In Ben Graham's calculation of liquidation value, Viva Biotech Holdings's accounts receivable are only considered to be worth 75% of book value:

Viva Biotech Holdings's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1005.3	-	3453.25	+	0.75 * 447.3	+	0.5 * 291.154
=	-1,967

Viva Biotech Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.

Executives

Mao Chen Cheney	2101 Beneficial owner
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings Headlines

No Headlines